Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
April 8, 2019 Off

Project Data Sphere Builds on Five Years of Success by Expanding Open-Access Data Platform and Broadening Research Programs that Accelerate New Cancer Patient Therapies

By BusinessWire

CARY, N.C.–(BUSINESS WIRE)–Five years ago, visionary researchers made a bold decision to create an open-access platform for cancer clinical trial…

April 8, 2019 Off

Navidea Biopharmaceuticals Receives FDA Feedback Regarding Rheumatoid Arthritis Clinical Trial Design and Provides Business Updates

By BusinessWire

Company Will Host Conference Call at 5:00 p.m. (ET) on Monday, April 8, 2019 DUBLIN, Ohio–(BUSINESS WIRE)–Navidea Biopharmaceuticals, Inc. (NYSE…

April 8, 2019 Off

Appili Therapeutics to Present at 2019 Bloom Burton & Co. Healthcare Investor Conference  

By BusinessWire

HALIFAX, Nova Scotia–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24IMV&src=ctag" target="_blank"gt;$IMVlt;/agt; lt;a href="https://twitter.com/hashtag/AntibioticDeveloper?src=hash" target="_blank"gt;#AntibioticDeveloperlt;/agt;–Appili Therapeutics Inc. (the “Company” or “Appili”), a biopharmaceutical company focused on…

April 8, 2019 Off

Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market 2019-2023 | 17% CAGR Projection over the Next Four Years | Technavio

By BusinessWire

LONDON–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/PARPinhibitors?src=hash” target=”_blank”gt;#PARPinhibitorslt;/agt;–The research report on the global PARP (poly ADP-ribose polymerase) inhibitors market by Technavio predicts the market…

April 8, 2019 Off

Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases

By BusinessWire

− Companies to Also Jointly Advance Select Number of Preclinical Disease Programs with Targets Expressed in the Liver and Treatments…

April 8, 2019 Off

Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases

By BusinessWire

− Companies to Also Jointly Advance Select Number of Preclinical Disease Programs with Targets Expressed in the Liver and Treatments…

April 8, 2019 Off

Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market 2019-2023 | 17% CAGR Projection over the Next Four Years | Technavio

By BusinessWire

LONDON–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/PARPinhibitors?src=hash" target="_blank"gt;#PARPinhibitorslt;/agt;–The research report on the global PARP (poly ADP-ribose polymerase) inhibitors market by Technavio predicts the market…

April 8, 2019 Off

Humacyte Awarded ‘Large Project Prototype of the Year’ from The Medical Technology Enterprise Consortium

By BusinessWire

Honor Recognizes Humacyte’s Progress in Accelerating the Manufacturing Platform and Process for Producing Vascular Conduits for Hemodialysis and Vascular Trauma…

April 8, 2019 Off

Humacyte Awarded ‘Large Project Prototype of the Year’ from The Medical Technology Enterprise Consortium

By BusinessWire

Honor Recognizes Humacyte’s Progress in Accelerating the Manufacturing Platform and Process for Producing Vascular Conduits for Hemodialysis and Vascular Trauma…

April 8, 2019 Off

Axonics® Appoints Nancy L. Snyderman, M.D. and Jane E. Kiernan to its Board of Directors

By BusinessWire

IRVINE, Calif.–(BUSINESS WIRE)–Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel…

Posts pagination

Previous 1 … 3,293 3,294 3,295 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine